within Pharmacolibrary.Drugs.ATC.L;

model L01XA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.008,
    k12             = 6.0,
    k21             = 6.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Carboplatin is a platinum-based chemotherapy drug commonly used for the treatment of various cancers, including ovarian, lung, head and neck, and testicular cancers. It interferes with DNA replication in cancer cells, resulting in cell death. Carboplatin is widely approved and used in clinical oncology today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult cancer patients with normal renal function. Population PK analysis. Intravenous infusion over 60 minutes.</p><h4>References</h4><ol><li><p>van der Vijgh, WJ (1991). Clinical pharmacokinetics of carboplatin. <i>Clinical pharmacokinetics</i> 21(4) 242–261. DOI:<a href=\"https://doi.org/10.2165/00003088-199121040-00002\">10.2165/00003088-199121040-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1760899/\">https://pubmed.ncbi.nlm.nih.gov/1760899</a></p></li><li><p>Machado, MC, et al., &amp; Estrela-Lima, A (2022). Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma. <i>Animals : an open access journal from MDPI</i> 12(22) –. DOI:<a href=\"https://doi.org/10.3390/ani12223109\">10.3390/ani12223109</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36428336/\">https://pubmed.ncbi.nlm.nih.gov/36428336</a></p></li><li><p>Ozols, RF, et al., &amp; Baergen, R (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 21(17) 3194–3200. DOI:<a href=\"https://doi.org/10.1200/JCO.2003.02.153\">10.1200/JCO.2003.02.153</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12860964/\">https://pubmed.ncbi.nlm.nih.gov/12860964</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XA02;
